Millipore Sigma Vibrant Logo

539652 PKCβII/EGFR Inhibitor - CAS 145915-60-2 - Calbiochem

The PKCβII/EGFR Inhibitor, also referenced under CAS 145915-60-2, controls the biological activity of PKCβII/EGFR. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: CG53353, DAPH 2, 4,5-bis(4-Fluoroanilino)-phthalimide, CGP 53 353

Primary Target: EGFR
View Products on Sigmaaldrich.com
539652
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      CAS #Empirical Formula
      145915-60-2C₂₀H₁₃F₂N₃O₂
      Description
      OverviewA cell-permeable symmetrical phthalimide compound that acts as a potent, reversible, and ATP-competitive inhibitor of EGFR and PKC isozymes α, βI, and βII (IC50 = 0.7 µM, 1.9 µM, 3.8 µM, and 0.41 µM, respectively). Only weakly inhibits the activity of a panel of 16 other kinases, including novel and atypical PKC isozymes. Reported to inhibit insulin-stimulated cellular 2-deoxyglucose uptake, osteoclast differentiation, ERK activation, and TLS/FUS DNA-binding activity in vitro. Also reported to exhibit antitumor activity in mice in vivo.
      Catalogue Number539652
      Brand Family Calbiochem®
      SynonymsCG53353, DAPH 2, 4,5-bis(4-Fluoroanilino)-phthalimide, CGP 53 353
      References
      ReferencesKouroedov, A., et al. 2004. Circulation 110, 91.
      Lee, S.W., et al. 2003. Bone 32, 217.
      Perrotti, D., et al. 1998. EMBO J. 17, 4442.
      Chalfant, C.E., et al. 1996. Mol. Endocrinol. 10, 1273.
      Buchdunger, E., et al. 1995. Clin. Cancer Res. 1, 813.
      Trinks, U., et al. 1994. J. Med. Chem. 37, 1015.
      Product Information
      CAS number145915-60-2
      ATP CompetitiveY
      FormOrange solid
      Hill FormulaC₂₀H₁₃F₂N₃O₂
      Chemical formulaC₂₀H₁₃F₂N₃O₂
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetEGFR
      Primary Target IC<sub>50</sub>0.7 µM, 1.9 µM, 3.8 µM, and 0.41 µM against EGFR and PKC isozymes α, βI, and βII, respectively
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      539652 0

      Documentation

      PKCβII/EGFR Inhibitor - CAS 145915-60-2 - Calbiochem MSDS

      Title

      Safety Data Sheet (SDS) 

      PKCβII/EGFR Inhibitor - CAS 145915-60-2 - Calbiochem Certificates of Analysis

      TitleLot Number
      539652

      References

      Reference overview
      Kouroedov, A., et al. 2004. Circulation 110, 91.
      Lee, S.W., et al. 2003. Bone 32, 217.
      Perrotti, D., et al. 1998. EMBO J. 17, 4442.
      Chalfant, C.E., et al. 1996. Mol. Endocrinol. 10, 1273.
      Buchdunger, E., et al. 1995. Clin. Cancer Res. 1, 813.
      Trinks, U., et al. 1994. J. Med. Chem. 37, 1015.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision11-January-2010 RFH
      SynonymsCG53353, DAPH 2, 4,5-bis(4-Fluoroanilino)-phthalimide, CGP 53 353
      DescriptionA cell-permeable, potent, ATP-competitive, and reversible inhibitor of EGFR and PKC isozymes α, βI, and βII (IC50 = 0.7 µM, 1.9 µM, 3.8 µM, and 0.41 µM, respectively). Only weakly inhibits the activity of a panel of 16 other kinases, including novel and atypical PKC isozymes. Reported to inhibit insulin-stimulated cellular 2-deoxyglucose uptake, osteoclast differentiation, ERK activation, and TLS/FUS DNA-binding activity in vitro. Also reported to exhibit antitumor activity in mice in vivo.
      FormOrange solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number145915-60-2
      Chemical formulaC₂₀H₁₃F₂N₃O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (20 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesKouroedov, A., et al. 2004. Circulation 110, 91.
      Lee, S.W., et al. 2003. Bone 32, 217.
      Perrotti, D., et al. 1998. EMBO J. 17, 4442.
      Chalfant, C.E., et al. 1996. Mol. Endocrinol. 10, 1273.
      Buchdunger, E., et al. 1995. Clin. Cancer Res. 1, 813.
      Trinks, U., et al. 1994. J. Med. Chem. 37, 1015.